BTX-1188 is under clinical development by BioTheryX and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Refractory Acute Myeloid Leukemia have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BTX-1188’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BTX-1188 is under development for the treatment of solid tumor, B-Cell non-Hodgkin lymphoma, relapsed acute myeloid leukemia, refractory acute myeloid leukemia. It acts by targeting GSPT1, IKZF1, IKZF3. The drug candidate is being developed based on the protein homeostatic modulator (PHM) technology platform. It is administered through oral route. It was also under development for the treatment of myelodysplastic syndrome.
BioTheryX is a clinical-stage biopharmaceutical company focusing on restoring protein homeostasis, including protein degradation and modulation, multi-kinase inhibition to develop treatments intended to improve and extend the quality-of-life of patients with life-threatening diseases. BioTheryX is headquartered in San Diego, California, the US.
For a complete picture of BTX-1188’s drug-specific PTSR and LoA scores, buy the report here.